Palatin halves workforce and puts all behind bremelanotide for sexual dysfunction
This article was originally published in Scrip
Executive Summary
Palatin Technologies is halving its workforce to 20 people and stopping all preclinical R&D activities in a bid to conserve cash. The company will use its funds to finance the clinical development of its lead candidate bremelanotide, for male and female sexual dysfunction, and PL-3994 for acute severe asthma.